ATE554070T1 - Hemmer der s1p1-bindung - Google Patents

Hemmer der s1p1-bindung

Info

Publication number: ATE554070T1
Authority: AT; Austria
Prior art keywords: group; nitrogen atom; group represented; optionally substituted; atom
Prior art date: 2007-08-01

Application number

AT08792064T

Other languages

English (en)

Inventor

Naoya Ono

Fumiyasu Shiozawa

Tetsuya Yabuuchi

Hironori Katakai

Original Assignee

Taisho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-01

Filing date

2008-08-01

Publication date

2012-05-15

2008-08-01 Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd

2012-05-15 Application granted granted Critical

2012-05-15 Publication of ATE554070T1 publication Critical patent/ATE554070T1/de

Links

102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 title abstract 2
101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229910052757 nitrogen Inorganic materials 0.000 abstract 3
125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010012438 Dermatitis atopic Diseases 0.000 abstract 1
101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
208000017442 Retinal disease Diseases 0.000 abstract 1
206010038923 Retinopathy Diseases 0.000 abstract 1
206010064930 age-related macular degeneration Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
201000008937 atopic dermatitis Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
208000002780 macular degeneration Diseases 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT08792064T 2007-08-01 2008-08-01 Hemmer der s1p1-bindung ATE554070T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007201274		2007-08-01
PCT/JP2008/063851 WO2009017219A1 (ja)	2007-08-01	2008-08-01	Ｓ１ｐ1結合阻害物質

Publications (1)

Publication Number	Publication Date
ATE554070T1 true ATE554070T1 (de)	2012-05-15

Family

ID=40304448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08792064T ATE554070T1 (de)	2007-08-01	2008-08-01	Hemmer der s1p1-bindung

Country Status (15)

Country	Link
US (1)	US8048898B2 (de)
EP (1)	EP2177512B1 (de)
JP (1)	JP5311057B2 (de)
CN (1)	CN101790517B (de)
AT (1)	ATE554070T1 (de)
CY (1)	CY1113057T1 (de)
DK (1)	DK2177512T3 (de)
ES (1)	ES2382697T3 (de)
HR (1)	HRP20120363T1 (de)
PL (1)	PL2177512T3 (de)
PT (1)	PT2177512E (de)
RS (1)	RS52368B (de)
RU (1)	RU2468009C2 (de)
SI (1)	SI2177512T1 (de)
WO (1)	WO2009017219A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201118876D0 (en) *	2011-11-01	2011-12-14	Astex Therapeutics Ltd	Pharmaceutical compounds
CN111683682A (zh)	2018-02-02	2020-09-18	国立大学法人京都大学	用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH05194412A (ja)	1991-12-28	1993-08-03	Advance Co Ltd	ジアゾリン化合物
GB9202791D0 (en) *	1992-02-11	1992-03-25	British Bio Technology	Compounds
DK0786455T3 (da)	1994-09-26	2004-03-29	Shionogi & Co	Imidazolderivater
DE60134735D1 (de)	2000-04-06	2008-08-21	Astrazeneca Ab	Neue neurokinin-antagonisten zum gebrauch als arzneimittel
US20020110604A1 (en)	2000-08-11	2002-08-15	Ashni Naturaceuticals, Inc.	Composition exhibiting synergistic antioxidant activity
EP1315735A4 (de)	2000-08-31	2005-04-06	Merck & Co Inc	Phosphat-derivate als immunoregulatorische verbindungen
JP2002212070A (ja)	2001-01-24	2002-07-31	Ono Pharmaceut Co Ltd	アスパラギン酸誘導体を有効成分として含有するスフィンゴシン−１−リン酸拮抗剤
PT1369419E (pt) *	2001-03-12	2007-08-16	Ono Pharmaceutical Co	Composto de n-fenilarilsulfonamida, fármaco contendo o composto como ingrediente activo, produtos intermédios para a produção do composto e processos para a produção do composto
JP2002332278A (ja)	2001-05-08	2002-11-22	Human Science Shinko Zaidan	Ｅｄｇ受容体拮抗作用を有する複素環誘導体
ES2316613T3 (es) *	2001-05-10	2009-04-16	Ono Pharmaceutical Co., Ltd.	Derivados de acido crboxilico y composiciones farmaceuticas que contienen los mismos como ingrediente activo.
HUP0400316A2 (hu) *	2001-05-22	2005-02-28	Neurogen Corporation	CRF1 modulátor hatású 5-szubsztituált-2-arilpiridin származékok és ezeket tartalmazó gyógyszerkészítmények
GB0113524D0 (en)	2001-06-04	2001-07-25	Hoffmann La Roche	Pyrazole derivatives
DE10130397A1 (de)	2001-06-23	2003-01-09	Bayer Cropscience Gmbh	Herbizide substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbzide und Pflanzenwachstumsregulatoren
WO2003029217A2 (en) *	2001-09-27	2003-04-10	Universite De Liege	Pyridinic sulfonamide derivatives, method of production and use thereof
JP4035759B2 (ja)	2001-11-06	2008-01-23	独立行政法人産業技術総合研究所	アミノアルコールリン酸化合物、製造方法、及びその利用方法
JP2005531506A (ja)	2002-03-01	2005-10-20	メルク　エンド　カムパニー　インコーポレーテッド	Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
WO2003074008A2 (en)	2002-03-01	2003-09-12	Merck & Co., Inc.	Aminoalkylphosphonates and related compounds as edg receptor agonists
PT1505959E (pt)	2002-05-16	2009-02-05	Novartis Ag	Utilização de agentes de ligação do receptor edg em cancro
JP2005533058A (ja)	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
CN100516024C (zh)	2002-09-13	2009-07-22	诺瓦提斯公司	氨基-丙醇衍生物
DE60335827D1 (de)	2002-12-20	2011-03-03	Merck Sharp & Dohme	1-(amino)indane als edg-rezeptoragonisten
TW200423930A (en)	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
US7425631B2 (en) *	2003-04-10	2008-09-16	Amgen Inc.	Compounds and methods of use
WO2004089367A1 (en)	2003-04-11	2004-10-21	Novo Nordisk A/S	Pharmaceutical use of substituted 1,2,4-triazoles
AU2004240586A1 (en)	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
EP1697333A4 (de)	2003-12-17	2009-07-08	Merck & Co Inc	(3,4-disubstituierte)propansäurecarboxylate als agonisten des s1p (edg) rezeptors
WO2005123677A1 (en)	2004-06-16	2005-12-29	Actelion Pharmaceuticals Ltd	4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
US8022225B2 (en) *	2004-08-04	2011-09-20	Taisho Pharmaceutical Co., Ltd	Triazole derivative
US20080161187A1 (en) *	2005-03-16	2008-07-03	Basf Aktiengesellschaft	Biphenyl-N-(4-Pyridyl) Methylsulfonamides
DE102005012482A1 (de) *	2005-03-16	2006-09-21	Basf Ag	Verfahren zur Herstellung von Polyoxymethylenen
BRPI0615133A2 (pt) *	2005-08-23	2011-05-03	Irm Llc	compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso
TW200736234A (en)	2006-01-17	2007-10-01	Astrazeneca Ab	Chemical compounds
RU2409570C2 (ru) *	2006-02-03	2011-01-20	Тайсо Фармасьютикал Ко., Лтд.	Производные триазола
CN101415687B (zh) *	2006-02-06	2012-02-08	大正制药株式会社	鞘氨醇-1-磷酸结合抑制物质
US8097644B2 (en) *	2006-03-28	2012-01-17	Allergan, Inc.	Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
WO2007122401A1 (en)	2006-04-21	2007-11-01	Astrazeneca Ab	Imidazole derivatives for use as edg-1 antagonists
EP2013184A1 (de)	2006-04-21	2009-01-14	AstraZeneca AB	Als edg-rezeptormodulatoren geeignete sulfonamidverbindungen

2008
- 2008-08-01 US US12/671,401 patent/US8048898B2/en not_active Expired - Fee Related
- 2008-08-01 RU RU2010107211/04A patent/RU2468009C2/ru not_active IP Right Cessation
- 2008-08-01 PL PL08792064T patent/PL2177512T3/pl unknown
- 2008-08-01 CN CN2008801013035A patent/CN101790517B/zh not_active Expired - Fee Related
- 2008-08-01 ES ES08792064T patent/ES2382697T3/es active Active
- 2008-08-01 PT PT08792064T patent/PT2177512E/pt unknown
- 2008-08-01 AT AT08792064T patent/ATE554070T1/de active
- 2008-08-01 RS RS20120266A patent/RS52368B/sr unknown
- 2008-08-01 SI SI200830618T patent/SI2177512T1/sl unknown
- 2008-08-01 JP JP2009525458A patent/JP5311057B2/ja not_active Expired - Fee Related
- 2008-08-01 WO PCT/JP2008/063851 patent/WO2009017219A1/ja not_active Ceased
- 2008-08-01 EP EP08792064A patent/EP2177512B1/de active Active
- 2008-08-01 HR HRP20120363AT patent/HRP20120363T1/hr unknown
- 2008-08-01 DK DK08792064.1T patent/DK2177512T3/da active
2012
- 2012-07-04 CY CY20121100601T patent/CY1113057T1/el unknown

Also Published As

Publication number	Publication date
SI2177512T1 (sl)	2012-06-29
DK2177512T3 (da)	2012-06-18
HK1143591A1 (en)	2011-01-07
CN101790517A (zh)	2010-07-28
CY1113057T1 (el)	2016-04-13
HRP20120363T1 (hr)	2012-05-31
EP2177512B1 (de)	2012-04-18
CN101790517B (zh)	2013-08-21
RU2010107211A (ru)	2011-09-10
EP2177512A4 (de)	2011-01-05
JPWO2009017219A1 (ja)	2010-10-21
ES2382697T3 (es)	2012-06-12
RS52368B (sr)	2012-12-31
RU2468009C2 (ru)	2012-11-27
PL2177512T3 (pl)	2012-09-28
JP5311057B2 (ja)	2013-10-09
US20100234594A1 (en)	2010-09-16
WO2009017219A1 (ja)	2009-02-05
US8048898B2 (en)	2011-11-01
EP2177512A1 (de)	2010-04-21
PT2177512E (pt)	2012-05-07

Publication	Publication Date	Title
EA201000413A1 (ru)	2010-06-30	Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида
MY177250A (en)	2020-09-10	Novel nicotinamide derivative or salt thereof
WO2008108378A3 (en)	2008-12-04	Bicyclic oxomorpholine derivative
MX2009009492A (es)	2009-09-15	Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
WO2008126933A3 (en)	2008-12-31	Process for producing pesticidal benzamide compounds
MX2009011769A (es)	2009-11-13	Derivados de piridona como inhibidores de mapk p38a.
EA201290401A1 (ru)	2013-01-30	Азотсодержащее гетероциклическое соединение и сельскохозяйственный фунгицид
WO2008108380A3 (en)	2009-04-16	Pyrrole compounds
MY153971A (en)	2015-04-30	Sulfonamides as trpm8 modulators
WO2008005368A3 (en)	2009-02-26	Piperazines as p2x7 antagonists
EA017861B9 (ru)	2014-05-30	Способ получения 4-оксохинолинового соединения
WO2010013567A1 (ja)	2010-02-04	アミド誘導体、該アミド誘導体を含有する有害生物防除剤および有害生物の防除方法
EA201000269A1 (ru)	2010-08-30	Новые гербициды
WO2008146914A1 (ja)	2008-12-04	複素環化合物
WO2008057775A3 (en)	2008-07-31	Heterocyclic amide compounds useful as kinase inhibitors
MX2009008509A (es)	2009-08-20	Compuesto de anillo puenteado-aza.
MY169179A (en)	2019-02-25	Novel piperidine compound or salt thereof
MX2010008361A (es)	2010-08-30	Derivados de arilamida oxazepinopirimidona sustituidos.
WO2009028280A1 (ja)	2009-03-05	ピラゾールカルボン酸誘導体及びその製造方法、並びに殺菌剤
EA201270359A1 (ru)	2012-09-28	Терапевтическое средство от расстройств настроения
MX336268B (es)	2016-01-13	Compuesto de amidina o sal del mismo.
EA201100920A1 (ru)	2012-01-30	Новые гербициды
MX2009008772A (es)	2009-08-25	Derivado piridil-triazolopirimidina o su sal, pesticida que lo contiene y proceso para su produccion.
ATE500212T1 (de)	2011-03-15	Bisphenol monoester
BR112013015774A2 (pt)	2018-05-22	compostos de pirazol tendo efeito terapêutico sobre mieloma múltiplo.